Hostname: page-component-78c5997874-v9fdk Total loading time: 0 Render date: 2024-11-05T01:47:53.141Z Has data issue: false hasContentIssue false
  • English
  • Français

Efficacy of Noradrenergic-Selective Agents in the Treatment of Neuropsychiatric Diseases

Published online by Cambridge University Press:  07 November 2014

Siegfried F. Kasper  and
Eva Resinger
Get access Rights & Permissions [Opens in a new window]

Abstract

In recent years, a number of antidepressants with varying degrees of selectivity for the noradrenergic neurotransmitter system have become available. However, these agents represent a pharmacologically heterogeneous group and differ in terms of their precise side-effect profile and, possibly, their clinical efficacy. Bupropion, which is thought to act on both the dopamine and norepinephrine (NE) systems, has not been widely used as an antidepressant and has more recently been licensed as adjunctive therapy for smoking cessation. The serotonin-NE reuptake inhibitors venlafaxine and nefazodone, the noradrenergic and specific serotonergic antide-pressant mirtazapine, and the selective NE reuptake inhibitor reboxetine (the only truly NE-selective agent available) have all demonstrated efficacy in the treatment of depressive disorders. Evidence is now emerging for their use in the treatment of anxiety and panic disorders. There is some suggestion of a role for noradrenergic agents in other disorders, including attention-deficit/hyper-activity disorder and social phobia. The full range of disorders for which noradrenergic agents can be used remains to be seen and further research in this area is necessary.

Type
Feature Articles
Information
CNS Spectrums , Volume 6 , Issue 8: Advances in the Neurobiology of Norepinephrine and its Relevance to Psychiatric Disorders , August 2001 , pp. 710 - 713
Copyright
Copyright © Cambridge University Press 2001

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

REFERENCES

1. Murray, CJL, Lopez, AD. A comprehensive assessment of mortality and disability from diseases, injuries and risk factors in 1990 and projected to 2020. In: The Global Burden of Disease. World Health Organization; 1998.Google Scholar
2. Feighner, JP. Mechanism of action of antidepressants medications. J Clin Psychiatry. 1999a; 60(Suppl 4): 4–13.Google ScholarPubMed
3. Horst, WD, Preskorn, SH. Mechanisms of action and clinical characteristics of three atypical antidepressants: venlafaxine, nefazodone, bupropion. J Affect Disord. 1998; 51: 237–254.CrossRefGoogle ScholarPubMed
4. Anderson, IM, Tomenson, BM. The efficacy of selective serotonin re-uptake inhibitors in depression: a meta-analysis of studies against tricyclic antidepressants. J Psychopharmacol. 1994; 8: 238–249.CrossRefGoogle ScholarPubMed
5. Anderson, IM, Tomenson, BM. Treatment discontinuation with selective serotonin reuptake inhibitors compared with tricyclic antidepressants: a meta-analysis. Br Med J. 1995; 310: 1433–1438.CrossRefGoogle ScholarPubMed
6. Schatzberg, AF. Clinical efficacy of reboxetine in major depression. In: Gorman, JM, Nemeroff, CB, eds. The role of norepinephrine in the treatment of depression. J Clin Psychiatry. 1999; 60: 623–631.Google Scholar
7. Humble, M. Noradrenaline and serotonin reuptake inhibition as clinical principlies: a review of antidepressant efficacy. Acta Psychiatr Scand Suppl. 2000; 402: 28–36.CrossRefGoogle ScholarPubMed
8. Boyce, P, Judd, F. The place for the tricyclic antidepressants in the treatment of depression. Aust N Z J Psychiatry. 1999: 33: 323–327.CrossRefGoogle ScholarPubMed
9. Coupland, N, Wilson, S, Nutt, D. Antidepressant drugs and the cardiovascular system: a comparison of tricyclics and selective serotonin reuptake inhibitors and their relevance for the treatment of psychiatric patients with cardiovascular problems. J Psychopharmacol. 1997; 11: 83–92.CrossRefGoogle ScholarPubMed
10. Davidson, JRT, Connor, KM. Bupropion sustained release: a therapeutic overview. J Clin Psychiatry. 1998; 59(Suppl 4): 25–31.Google ScholarPubMed
11. Hirschfeld, RM. Efficacy of SSRIs and newer antidepressants in severe depression: comparison with TCAs. J Clin Psychiatry. 1999; 60: 326–335.CrossRefGoogle ScholarPubMed
12. Croft, H, Settle, E Jr, Houser, T et al. , A placebo-controlled comparison of the antidepressant efficacy and effects on sexual functioning of sustained-release bupropion and sertraline. Clin Ther. 1999; 21: 643–658.CrossRefGoogle ScholarPubMed
13. Kiev, A, Masco, HL, Wenger, TL et al. , The cardiovascular effects of bupropion and nortriptyline in depressed outpatients. Ann Clin Psychiatry. 1994; 6: 107–115.CrossRefGoogle ScholarPubMed
14. Weihs, KL, Settle, EC Jr, Batey, SR et al. , Bupropion sustained release versus paroxetine for the treatment of depression in the elderly. J Clin Psychiatry. 2000; 61: 196–202.CrossRefGoogle ScholarPubMed
15. Holliday, SM, Benfield, P. Venlafaxine: a review of its pharmacology and therapeutic potential in depression. Drugs. 1995; 49: 280–294.CrossRefGoogle ScholarPubMed
16. Cunningham, LA (for the Venlafaxine XR 208 Study Group). Once-daily extended release (XR) and venlafaxine immediate release in outpatients with major depression. Ann Clin Psychiatry. 1997; 14: 99–106.Google Scholar
17. Einarson, TR, Arikian, SR, Casciano, J, Doyle, JJ. Comparison of extended-release venlafaxine, selective serotonin reuptake inhibitors and tricyclic antidepressants in the treatment of depression: a meta-analysis of randomized controlled trials. Clin Ther. 1999; 21: 296–308.CrossRefGoogle ScholarPubMed
18. Thase, ME. Effects of venlafaxine on blood pressure: a meta-analysis of original data from 3744 depressed patients. J Clin Psychiatry. 1998; 59: 502–508.CrossRefGoogle ScholarPubMed
19. Augustin, BG, Cold, JA, Jann, MW. Venlafaxine and nefazodone, two pharmacologically distinct antidepressants. Pharmacotherapy. 1997; 17: 511–530.CrossRefGoogle ScholarPubMed
20. Gorman, JM, Sullivan, G. Noradrenergic approaches to antidepressant therapy. J Clin Psychiatry. 2000; 61(Suppl 1): 13–16.Google ScholarPubMed
21. Guelfi, JD, White, C, Hackett, D et al. , Effectiveness of venlafaxine in patients hospitalized for major depression and melancholia. J Clin Psychiatry. 1995; 56: 450–458.Google ScholarPubMed
22. Davis, R, Whittington, R, Bryson, HM. Nefazodone. A review of its pharmacology and clinical efficacy in the management of major depression. Drugs. 1997; 53: 608–636.CrossRefGoogle ScholarPubMed
23. Feiger, A, Kiev, A, Shrivastava, RK. Nefazodone versus sertraline in outpatients with major depression: focus on efficacy, tolerability and effects on sexual function and satisfaction. J Clin Psychiatry. 1996; 57: 53–62.Google ScholarPubMed
24. Feighner, J, Targum, SD, Bennett, ME et al. , A double-blind placebo-controlled trial of nefazodone in the treatment of patients hospitalized for major depression. J Clin Psychiatry. 1998; 59: 246–253.CrossRefGoogle ScholarPubMed
25. Kasper, S, El-Giamal, N, Hilger, E. Reboxetine: the first selective noradrenaline reuptake inhibitor (selective NRI). Expert Opin Pharmacother. 2000; 1: 771–782.CrossRefGoogle Scholar
26. Holm, KJ, Spencer, CM. Reboxetine: a review of its use in depression. CNS Drugs. 1999; 12: 66–83.CrossRefGoogle Scholar
27. Montgomery, SA. Reboxetine: additional benefits to the depressed patient. J Psychopharmacol. 1997; 11(Suppl 1): S9–S15.Google Scholar
28. Kasper, S. Treatment benefits of reboxetine. International Journal of Psychiatry in Clinical Practice. 1999; 3: S3–S8.Google Scholar
29. Dubini, A, Bose, M, Polin, V. Noradrenaline-selective versus serotonin-selective antidepressant therapy: differential effects on social functioning. J Psychopharmacol. 1997; 11: S17–S23.Google ScholarPubMed
30. Versiani, M, Mehilane, L, Gaszner, P et al. , Reboxetine, a unique selective NRI, prevents relapse and recurrence in long-term treatment of major depressive disorder. J Clin Psychiatry. 1999; 60: 400–406.CrossRefGoogle ScholarPubMed
31. Versiani, M. Reboxetine, a novel selective NRI, in the treatment of panic disorder [Abstract P.I.067]. Eur Neuropsychopharmacol. 2000; 10 (Suppl 3): 245.Google Scholar
32. Holm, KJ, Markham, A. Mirtazapine. a review of its use in major depression. Drugs. 1999; 57: 607–631.CrossRefGoogle ScholarPubMed
33. Scates, AC, Doraiswamy, PM. Reboxetine: a selective norepinephrine reuptake inhibitor for the treatment of depression. Ann Pharmacother. 2000; 34: 1302–1312.CrossRefGoogle ScholarPubMed
34. Mucci, M. Reboxetine: a review of antidepressant tolerability. J Psychopharmacol. 1997; 11 (Suppl 4): S33–S37.Google ScholarPubMed
35. Montgomery, SA. Predicting response: noradrenaline reuptake inhibition. Int Clin Psychopharmacol. 1999; 14: S21–S26.CrossRefGoogle ScholarPubMed
36. Montgomery, SA, Reimitz, PE, Zivkov, M. Mirtazapine versus amitriptyline in the long-term treatment of depression: a double-blind placebo-controlled study. Int Clin Psychopharmacol. 1998; 13: 63–73CrossRefGoogle ScholarPubMed
37. Schatzberg, AF. New indications for antidepressants. J Clin Psychiatry. 2000; 61(Suppl 11): 9–17.Google ScholarPubMed
38. Feighner, JP. Overview of antidepressants currently used to treat anxiety disorders. J Clin Psychiatry. 1999b; 60(Suppl 22): 18–22.Google ScholarPubMed
39. Sheehan, DV. Venlafaxine extended release (XR) in the treatment of generalized anxiety disorder. J Clin Psychiatry. 1999; 60(Suppl 22): 23–28.Google ScholarPubMed
40. Gorman, JM. The use of newer antidepressants for panic disorder. J Clin Psychiatry. 1997; 58(Suppl 14): 54–59.Google ScholarPubMed
41. Falkai, P. Mirtazapine: other indications. J Clin Psychiatry. 1999; 60(Suppl 17): 36–39.Google ScholarPubMed
42. Papp, LA, Coplan, JD, Martinez, JM et al. , Efficacy of open-label nefazodone treatment in patients with panic disorder. J Clin Psychopharmacol. 2000; 20: 544–546.CrossRefGoogle ScholarPubMed